Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
2005
Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
2010 StandoutScience
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
2007
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
2007
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
2012
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease.
2006
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2011
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
2010
Engineering precision nanoparticles for drug delivery
2020 Standout
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
2008
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
2017
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft‐versus‐host disease after allogeneic transplantation
2005
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
2004
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
2008
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
2006
Crohn's disease
2012 Standout
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
2017
Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score
2019
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Allogeneic Transplantation for the Elderly Patient With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
2006
Acute myeloid leukaemia
2006
Utility of positron emission tomography scans in mantle cell lymphoma
2011
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Engineered T cells: the promise and challenges of cancer immunotherapy
2016
Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma
2007
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
2015
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
2020 Standout
Development, maintenance and disruption of the blood-brain barrier
2013 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Graft-versus-host disease
2009 Standout
Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
2008
Immunity, Inflammation, and Cancer
2010 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation
2005
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
2008 Standout
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
2016
Cancer immunotherapy comes of age
2011 StandoutNature
Risk assessment in haematopoietic stem cell transplantation: Viral status
2007
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia
2019
Idarucizumab for Dabigatran Reversal
2015 Standout
Gene Map of the HLA Region, Graves’ Disease and Hashimoto Thyroiditis, and Hematopoietic Stem Cell Transplantation
2015
Novel treatment strategies in clear-cell metastatic renal cell carcinoma
2005
Comprehensive analysis of the clinical immuno-oncology landscape
2017
Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease
2011
A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
2010
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
2004
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
2006
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)
2005
Therapy with azanucleosides for myelodysplastic syndromes
2010
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐ and transplantation‐related factors
2009
Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival
2011
Cancer-related inflammation
2008 StandoutNature
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
2009
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
2017
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Adoptive Immunotherapy for Cancer or Viruses
2014
How I treat refractory acute GVHD
2007
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies
2008
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
2020 Standout
Regulatory T Cells and Human Disease
2020 StandoutNobel
Acute Myeloid Leukemia
2015 Standout
Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival
2008
Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group
2008
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Cytarabine, Ki‐67, and SOX11 in patients with mantle cell lymphoma receiving rituximab‐containing autologous stem cell transplantation during first remission
2013
A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation
2008
Multiple Sclerosis
2018 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease
2007
Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication
2010
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
2006
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
2005
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
2010
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
2014
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
2008
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
2007
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
2010
Chimeric Antigen Receptor Therapy
2018 Standout
Metabolic reprogramming and cancer progression
2020 StandoutScience
Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation
2006
Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients
2018
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
2014
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
2004
How I treat multiple myeloma in younger patients
2009
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
2007
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
2014
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Multiple Myeloma
2011 Standout
Diabetes Impairs Hematopoietic Stem Cell Mobilization by Altering Niche Function
2011
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Works of Chitra Hosing being referenced
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
2008
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
2013
Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia
2010
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
2017
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
2008
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment
2009
Tacrolimus‐associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
2003
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
2005
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial
2008
CARs in Chronic Lymphocytic Leukemia – Ready to Drive
2012
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma
2007
West Nile Encephalitis in 2 Hematopoietic Stem Cell Transplant Recipients: Case Series and Literature Review
2003
Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections
2013
Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma
2009
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
2007
Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion
2010
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
2013
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR
2011
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
2004
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
2005
Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease: Does It Work?
2006
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
2004
Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan
2007
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
2006
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
2007
Tumor necrosis factor-α blockade for the treatment of acute GVHD
2004
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.
2008
Stem cell transplantation outcomes in lymphoblastic lymphoma
2016
Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation
2004
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
2003
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.
2003
Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas
2005
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
2003
Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections
2014
Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
2011
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
2005
The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation
2012
Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.
2005
Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis
2013
Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.
2006
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
2005
Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT
2008
Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
2015
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
2009
15 Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft versus host disease
2003
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
2009
Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression
2013
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease
2009